Organ-on-a-Chip and Lab-Grown Organoids

Drug development fails 90 percent of the time in Phase 2 because animal models do not replicate human biology. Organ-on-a-chip devices and patient-derived organoids replace animal testing. FDA Modernization Act 2.0 in 2022 explicitly allows these models. Emulate Bio lung-on-a-chip correctly predicted COVID-19 lung damage before autopsy data was available. By 2030 these platforms are expected to reduce Phase 2 trial failure rates by 30 to 40 percent.